The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study

BMC Cancer

Table 1 Clinicopathological characteristics of invasive lobular carcinoma, invasive ductal carcinoma, and luminal A subtype

Characteristic		ILC		IDC		P	LA-IDC		P
		(N = 83)		(N = 2833)			(N = 1088)
		n	%	n	%		n	%
Mean age (years)		48.3 ± 8.5		48.2 ± 10.5		0.93	47.9 ± 10.2		0.71
pT	T1	33	40.2	1730	61.2	0.001	667	61.4	0.001
	T2	45	54.9	986	34.9		373	34.4
	T3	4	4.9	89	3.1		37	3.4
	T4	0	0	23	0.8		9	0.8
	Unknown	1		5			2
pN	N0	46	56.1	1639	58.7	0.18	551	51.5	0.25
	N1	24	29.3	763	27.3		333	31.2
	N2	5	6.1	276	9.9		128	12
	N3	7	8.5	116	4.2		57	5.3
	Unknown	1		39			19
M	M0	83	100	2777	98	0.19	1064	97.8	0.17
	M1	0	0	56	2		24	2.2
Stage	I	25	30.1	1184	41.9	0.06	426	39.3	0.15
	II	44	53	1248	44.2		476	44
	III	14	16.9	337	11.9		157	14.5
	IV	0	0	56	2		24	2.2
	Unknown	0		8			5
HG	1 or 2	75	90.4	1438	54.9	<0.001	576	57.3	<0.001
	3	8	9.6	1183	45.1		429	42.7
	Unknown			212			83
ER	Positive	75	90.4	1825	64.4	<0.001	·	·	·
	Negative	8	9.6	1008	35.6		·	·
PgR	Positive	59	71.1	1420	50.1	<0.001	·	·	·
	Negative	24	28.9	1413	49.9		·	·
HER2	Negative	79	97.5	1586	74.6	<0.001	·	·	·
	Positive	2	2.5	540	25.4		·	·
	Unknown *	2		707			·	·
Subtype	Luminal A	74	91.4	1088	51.2	<0.001	·	·	·
	Non-LA	7	8.6	1038	48.8		·	·
	Unknown	2		707			·	·
p53	0 or 1+	74	93.7	2146	77.7	0.001	951	89.7	0.26
	2+ or 3+	5	6.3	616	22.3		109	10.3
	Unknown	4		71			28
Ki-67		10.3 ± 10.6		20.6 ± 19.8		<0.001	13.5 ± 13.2		0.03
Operation	BCS	57	68.7	2109	75.1	0.18	786	73	0.39
	Mastectomy	26	31.3	698	24.9		290	27
	None	0	0	26			3
Adjuvant therapy
Chemotherapy	Yes	68	81.9	2383	84.1	0.59	922	84.7	0.49
	No	15	18.1	450	15.9		166	15.3
Hormone therapy	Yes	79	95.2	2113	74.6	<0.001	1057	97.2	0.31
	No	4	4.8	720	25.4		31	2.8
Anti-HER2 therapy	Yes^†	1	1.2	164	5.8	0.08	·	·	·
	No	82	98.8	2669	94.2		·	·
Radiotherapy	Yes	64	77.1	2323	82	0.25	879	80.8	0.41
	No	19	22.9	510	18		209	19.2

* Including 2+ for HER2 by immunohistochemistry without FISH.
† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial [25] and 53 patients were enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial [26].
BCS, breast-conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.

ISSN: 1471-2407